Text Size

Alternate-Day Buprenorphine Administration. Phase I - 3

This study has been completed.
Sponsor:
Collaborator:
University of Vermont
Information provided by:
National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:
NCT00000221
First received: September 20, 1999
Last updated: June 23, 2005
Last verified: November 1993
History of Changes
  Purpose

The purpose of this study is to determine if two times a subject's daily maintenance dose will hold for 48 hours without changes in agonist and antagonist effects.


Condition Intervention Phase
Opioid-Related Disorders
 Drug: Buprenorphine
 Phase 1

Study Type: Interventional
Study Design: Intervention Model: Crossover Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Alternate-Day Buprenorphine Administration. Phase I

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Drug use
  • Opioid withdrawal
  • Opioid agonist effects
  • Dose identification
  • Pupil diameter

Estimated Enrollment: 0
Study Start Date: April 1992
  Eligibility

Ages Eligible for Study:   28 Years to 45 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Please contact site for information.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00000221

Locations
United States, Vermont
Treatment Research Center
Burlington, Vermont, United States, 05401
Sponsors and Collaborators
National Institute on Drug Abuse (NIDA)
University of Vermont
Investigators
Principal Investigator: Warren Bickel, Ph.D. University of Vermont
  More Information

Publications:

ClinicalTrials.gov Identifier: NCT00000221     History of Changes
Other Study ID Numbers: NIDA-06969-3, R01-06969-3
Study First Received: September 20, 1999
Last Updated: June 23, 2005
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Opioid-Related Disorders
Substance-Related Disorders
Mental Disorders
Buprenorphine
Analgesics, Opioid
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
 Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Central Nervous System Depressants
Narcotic Antagonists
Narcotics

ClinicalTrials.gov processed this record on May 16, 2013